8/2/2013

The European Commission approved Aegerion Pharmaceuticals' Lojuxta, or lomitapide, as an adjunct therapy to low-fat diet and other lipid-lowering drugs in patients with homozygous familial hypercholesterolemia. The approval was based on data from a late-stage trial.

Related Summaries